Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial f…
Biotechnology
US, Redwood City [HQ]
Ratios
7 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross Margin | - - | 100.00 | -83.36 | -207.68 | 75.05 | 72.71 | 19.61 | |
| Profit Margin | - - | -207.24 | -95.25 | -251.63 | -611.67 | -702.95 | -3,768.28 | |
| Operating Margin | - - | -200.00 | -108.15 | -257.54 | -639.70 | -730.01 | -4,207.12 | |
|
EPS Growth
|
- - | -35.29 | 29.57 | -100.00 | -52.47 | -24.70 | -25.33 | |
| EPS USD | -85.00 | -115.00 | -81.00 | -162.00 | -247.00 | -308.00 | -386.00 | |
| Return on Assets (ROA) | -206.45 | -24.50 | -21.61 | -19.06 | -24.36 | -30.63 | -20.89 | |
| Return on Equity (ROE) | -686.98 | -43.23 | -31.25 | -22.79 | -29.83 | -36.30 | -23.89 | |
| Return on Invested Capital (ROIC) | -689.34 | -39.40 | -32.10 | -21.74 | -27.00 | -34.41 | -25.25 | |
| Solvency | ||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | 1.41 | 0.87 | 5.76 | 9.03 | 7.91 | 4.21 | |
| Debt/Equity | - - | 2.48 | 1.25 | 6.88 | 11.06 | 9.37 | 4.82 | |
| Debt/EBITDA | 30.43 | 173.99 | 33.93 | 66.02 | 22.38 | 39.02 | 127.27 | |
|
Debt/Capitalization
|
- - | 2.42 | 1.24 | 6.44 | 9.96 | 8.57 | 4.59 | |
| Long-Term Debt/Capitalization | - - | 2.28 | 1.13 | 5.76 | 9.11 | 7.73 | 4.23 | |
| Interest Debt per Share USD | - - | 0.07 | 0.03 | 0.49 | 0.92 | 0.68 | 0.78 | |
| Debt Growth | - - | - - | 17.01 | 18,890.70 | 104.00 | -3.64 | 36.97 | |
| Liquidity | ||||||||
| Current Ratio | 124.26 | 279.62 | 311.21 | 962.61 | 3,048.20 | 1,065.09 | 1,306.41 | |
| Quick Ratio | 119.49 | 251.67 | 305.43 | 947.80 | 3,079.52 | 1,048.04 | 1,288.98 | |
| Cash Ratio | 119.49 | 227.76 | 38.70 | 221.02 | 573.12 | 260.41 | 483.94 | |
| Operating Cash Flow Ratio | -300 | - - | -100 | -200 | -700 | -300 | -200 | |
| Turnover | ||||||||
| Inventory Turnover | - - | - - | - - | - - | -57.65 | - - | - - | |
| Receivables Turnover | - - | 276.12 | 572.75 | 672.35 | 495.70 | 757.12 | 923.45 | |
| Payables Turnover | - - | - - | 804.87 | 1,048.87 | 52.16 | 45.32 | 15.07 | |
|
Asset Turnover
|
- - | 11.82 | 22.69 | 7.58 | 3.98 | 4.36 | 0.55 | |
| Fixed Turnover | - - | 293.44 | 700.17 | 118.29 | 41.26 | 47.98 | 11.58 | |
| Coverage | ||||||||
| Interest Coverage | -30,222.33 | -34,766.38 | -51,056.60 | -155,911.27 | -1,566,733.33 | 2,674.80 | -160,787.13 | |
| Asset Coverage | - - | 52,400 | 67,200 | 1,400 | 900 | 1,000 | 2,100 | |
| Cash Flow Coverage (CFGR) | - - | 50.52 | -2,593.62 | -306.34 | -220.88 | -349.51 | -398.63 | |
| EBITDA Coverage | -28,900 | -34,400 | -45,800 | -152,700 | -1,558,900 | 2,500 | -157,700 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -2.95 | -3.97 | -2.80 | -4.10 | -9.81 | -12.95 | -13.45 | |
|
Price/Earnings (P/E)
|
-3,386.36 | -2,522.37 | -3,577.39 | -2,437.79 | -1,019.37 | -772.21 | -743.67 | |
| Price/Earnings Growth (PEG) | - - | -71.47 | 121.00 | -24.38 | -19.43 | -31.27 | -29.37 | |
|
Price/Book (P/B)
|
23,263.59 | 1,090.51 | 1,117.86 | 555.47 | 304.12 | 280.29 | 177.70 | |
| Price/Tangible Book (P/TB) | 23,263.59 | 1,090.51 | 1,117.86 | 555.47 | 304.12 | 280.29 | 177.70 | |
| Price/Sales (P/S) | - - | 5,227.24 | 3,407.46 | 6,134.25 | 6,235.21 | 5,428.28 | 28,023.65 | |
|
Price/Cash Flow (P/CF)
|
-4,191.48 | 86,898.04 | -3,436.64 | -2,635.00 | -1,245.09 | -855.84 | -925.67 | |
| Price/Free CF (P/FCF) | -3,944.44 | -368,557.06 | -3,266.21 | -2,559.96 | -1,192.21 | -816.49 | -905.70 | |
| Price/Operating CF (P/OCF) | -4,191.48 | 86,898.04 | -3,436.64 | -2,635.00 | -1,245.09 | -855.84 | -925.67 |